- Home
- SYRE
as 07-05-2024 2:37pm EST
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.3B | IPO Year: | 2016 |
| Target Price: | $43.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -46.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.43 - $47.97 | Next Earning Date: | 08-09-2024 |
| Revenue: | $688,000 | Revenue Growth: | -40.94% |
| Revenue Growth (this year): | 820.99% | Revenue Growth (next year): | -25.00% |
Latest Spyre Therapeutics Inc. News
SYRE Breaking Stock News: Dive into SYRE Ticker-Specific Updates for Smart Investing
PR Newswire
17 days ago
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
PR Newswire
a month ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
a month ago
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
PR Newswire
2 months ago
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
PR Newswire
2 months ago
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
2 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
3 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
4 months ago
Spyre Therapeutics Announces $180 Million Private Placement
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRE Spyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.